Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

February 19, 2026

Study Completion Date

February 19, 2026

Conditions

Multiple System AtrophyMSA - Multiple System Atrophy

Interventions

BIOLOGICAL

hOMSC300

Human Oral Mucosa Stem Cells

Trial Locations (1)

Tel-Aviv Sourasky Medical Center (Ichilov), Tel Aviv

All Listed Sponsors

lead

Cytora Ltd.

INDUSTRY